VBIV Past Earnings image   This VBIV past earnings page last updated 11/19/2021
VBIV Past Earnings
Data adjusted for VBIV split history

PeriodPast Earnings DateGAAP
Q3 202111/8/2021-0.060
Q2 20218/2/2021-0.070
Q1 20215/10/2021-0.070
Q4 20203/2/2021-0.060
Q3 202011/2/2020-0.060
Q2 20207/31/2020-0.040
Q1 20205/6/2020-0.050
Q4 20193/5/2020-0.020
Q3 201911/6/2019-0.150
Q2 20198/9/2019-0.130
Q1 20195/1/2019-0.150
Q4 20182/25/2019-0.28
Q3 201811/9/2018-0.24
Q2 20187/26/2018-0.26
Q1 20185/1/2018-0.19
VBIV Past Revenue
PeriodPast Earnings DateGAAP
Q3 202111/8/20210.00B
Q2 20218/2/20210.00B
Q1 20215/10/20210.00B
Q4 20203/2/20210.00B
Q3 202011/2/20200.00B
Q2 20207/31/20200.00B
Q1 20205/6/20200.00B
Q4 20193/5/20200.00B
Q3 201911/6/20190.00B
Q2 20198/9/20190.00B
Q1 20195/1/20190.00B
Q4 20182/25/20192.68M
Q3 201811/9/2018259000
Q2 20187/26/2018234000
Q1 20185/1/2018178000

VBIV Past Earnings Q&A

What was the best and worst VBIV past earnings results?
For VBI Vaccines, I'm wondering what the company's very best and worst earnings results have been, on an earnings per share basis?

✔️Accepted answer: The highest VBIV past earnings result in our data set was -0.020/share posted in Q4 2019, while the lowest was in Q4 2018 when VBIV posted -0.28/share.

  Suggested answer: The biggest top line earnings performance — aka revenue — quarter was in Q4 2018 when VBIV reported 2.68M in revenue, while the quarter with the lowest revenue in our data set was Q3 2021 at 0.00B of revenue.

  Suggested answer: There are 15 VBIV past earnings results in our data set.

On this page we presented the VBIV past earnings date information for VBI Vaccines. Reviewing that VBIV Past Earnings for the company, we see that the highest past earnings result in our data set was in Q4 2019, when VBIV posted gaap of -0.020/share. Meanwhile the lowest VBIV past earnings result was in Q4 2018, when VBIV posted gaap of -0.28/share. Turning to top line revenue performance, the biggest revenue quarter in our data set was seen in Q4 2018 when VBIV reported 2.68M in revenue, while the smallest revenue quarter was Q3 2021 when VBIV reported 0.00B in revenue.

Any self directed investor doing their due diligence on VBIV or any other given stock can benefit from researching all of the VBI Vaccines past earnings — and here, we present each quarter's result all together on one page for easy comparison. Studying this information can help when projecting future earnings, as well as determining whether the past earnings trajectory justifies the current stock value. That's why we bring you PastEarnings.com to make it easy for investors to investigate VBI Vaccines past earnings, or the past earnings information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for VBIV. Thanks for visiting, and the next time you need to research VBIV past earnings or those of another stock, we hope you'll think of our site, as your go-to past earnings research resource of choice.

VBIV Past Earnings | www.PastEarnings.com | Copyright © 2020 - 2021, All Rights Reserved

Nothing in PastEarnings.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.